AstraZeneca Says Coronavirus Vaccine Shows Increased Response on Third Dose
13 Janeiro 2022 - 04:56AM
Dow Jones News
By Joe Hoppe
AstraZeneca PLC said Thursday that new preliminary data shows
its Vaxzevria coronavirus vaccine showed increased antibody
response against several coronavirus variants after a third dose,
or booster.
The pharmaceutical giant said that the positive results come
from a safety and immunogenicity trial, which showed the drug
increased immune responses against the Beta, Delta, Alpha and Gamma
variants of the virus, and was generally well tolerated. A separate
analysis of samples from the trial showed increased antibody
response to the Omicron variant as well, the company said.
The results came from individuals previously vaccinated with
Vaxzevria or an mRNA vaccine. However, AstraZeneca said that a
separate Phase 4 trial showed a third dose of Vaxzevria
substantially increased antibody levels in individuals that were
primarily vaccinated with Sinovac Biotech Ltd.'s vaccine CoronaVac,
which it said adds to growing evidence Vaxzevria can be used as a
booster regardless of primary vaccinations.
"Given the ongoing urgency of the pandemic and Vaxzevria's
increased immune response to the Omicron variant, we will continue
to progress regulatory submissions around the world for its use as
a third-dose booster," Mene Pangalos, biopharmaceuticals research
and development executive vice president said.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
January 13, 2022 02:41 ET (07:41 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024